Zhang H, Perez R, Krishnan J, Lautenbach E, Anderson D
Open Forum Infect Dis. 2023; 10(12):ofad561.
PMID: 38130594
PMC: 10733196.
DOI: 10.1093/ofid/ofad561.
Zlatkov N, Nasman M, Uhlin B
Microbiol Spectr. 2022; 10(5):e0067822.
PMID: 36169422
PMC: 9602443.
DOI: 10.1128/spectrum.00678-22.
Piatti G, De Ferrari L, Schito A, Riccio A, Penco S, Cassia S
Microorganisms. 2021; 9(7).
PMID: 34361936
PMC: 8307267.
DOI: 10.3390/microorganisms9071501.
Osman K, Kappell A, Elhadidy M, Elmougy F, Abd El-Ghany W, Orabi A
Sci Rep. 2018; 8(1):5859.
PMID: 29643424
PMC: 5895583.
DOI: 10.1038/s41598-018-23962-7.
Soundararajan N, Shanmugam P, Devanbu C, Sattar S
Int J Appl Basic Med Res. 2016; 6(4):258-261.
PMID: 27857893
PMC: 5108102.
DOI: 10.4103/2229-516X.192603.
Susceptibility to β-lactams and quinolones of Enterobacteriaceae isolated from urinary tract infections in outpatients.
Marchisio M, Porto A, Joris R, Rico M, Baroni M, Di Conza J
Braz J Microbiol. 2015; 46(4):1155-9.
PMID: 26691475
PMC: 4704613.
DOI: 10.1590/S1517-838246420140880.
Global Phenotypic Characterization of Effects of Fluoroquinolone Resistance Selection on the Metabolic Activities and Drug Susceptibilities of Clostridium perfringens Strains.
Park M, Rafii F
Int J Microbiol. 2015; 2014:456979.
PMID: 25587280
PMC: 4283427.
DOI: 10.1155/2014/456979.
Molecular Characterization of Uropathogenic Escherichia coli: Nalidixic Acid and Ciprofloxacin Resistance, Virulent Factors and Phylogenetic Background.
Basu S, Mukherjee S, Hazra A, Mukherjee M
J Clin Diagn Res. 2014; 7(12):2727-31.
PMID: 24551624
PMC: 3919340.
DOI: 10.7860/JCDR/2013/6613.3744.
Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens.
Park S, Park M, Rafii F
BMC Microbiol. 2013; 13:50.
PMID: 23452396
PMC: 3599539.
DOI: 10.1186/1471-2180-13-50.
Urinary tract infection in a rural community of Nigeria.
Oladeinde B, Omoregie R, Olley M, Anunibe J
N Am J Med Sci. 2012; 3(2):75-7.
PMID: 22540069
PMC: 3336890.
DOI: 10.4297/najms.2011.375.
The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia.
Camins B, Marschall J, DeVader S, Maker D, Hoffman M, Fraser V
J Hosp Med. 2011; 6(6):344-9.
PMID: 21834116
PMC: 3156036.
DOI: 10.1002/jhm.877.
Putative link between the virulence-associated fluA gene and fluoroquinolone resistance in uropathogenic Escherichia coli.
Luthje P, Brauner A
J Clin Microbiol. 2009; 48(2):675-6.
PMID: 19955281
PMC: 2815620.
DOI: 10.1128/JCM.01443-09.
(CGG)4-based PCR as a novel tool for discrimination of uropathogenic Escherichia coli strains: comparison with enterobacterial repetitive intergenic consensus-PCR.
Adamus-Bialek W, Wojtasik A, Majchrzak M, Sosnowski M, Parniewski P
J Clin Microbiol. 2009; 47(12):3937-44.
PMID: 19846645
PMC: 2786682.
DOI: 10.1128/JCM.01036-09.
Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns.
Takahashi A, Muratani T, Yasuda M, Takahashi S, Monden K, Ishikawa K
J Clin Microbiol. 2009; 47(3):791-5.
PMID: 19158256
PMC: 2650943.
DOI: 10.1128/JCM.01740-08.
Catheter-associated and nosocomial urinary tract infections: antibiotic resistance and influence on commonly used antimicrobial therapy.
Milan P, Ivan I
Int Urol Nephrol. 2008; 41(3):461-4.
PMID: 18787972
DOI: 10.1007/s11255-008-9468-y.
Virulence factors in urinary Escherichia coli strains: phylogenetic background and quinolone and fluoroquinolone resistance.
Piatti G, Mannini A, Balistreri M, Schito A
J Clin Microbiol. 2007; 46(2):480-7.
PMID: 18057134
PMC: 2238073.
DOI: 10.1128/JCM.01488-07.
Virulence factors in Escherichia coli.
Johnson J
J Clin Microbiol. 2005; 43(12):6221.
PMID: 16333140
PMC: 1317222.
DOI: 10.1128/JCM.43.12.6221-6222.2005.